In 2020, oncology is the strategic priority of many life science leaders. Global revenues in the oncology market are expected to more than double—from $104 billion in 2017 to $233 billion by 2024. Fueling this growth is a rich oncology pipeline, including more than 700 molecules in late-stage development as of 2017.
In light of increasing competition, newer entrants to the field are facing a number of challenges that are unique or more acute to this discipline, not the least of which is a target audience that is overworked and hard to reach—the community oncologist.
Community oncologists are responsible for treating the majority of the growing American population with cancer. Due to the proliferation of commercialized oncology drugs, they are also the target of a growing number of pharmaceutical sales representatives. But oncologists’ ever expanding responsibilities are taxing the time and resources needed to maximize patient care.
